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Meprin metalloproteinases have been shown to play a role in the progression of diabetic 
nephropathy (DN) in both mice and humans.  However, the mechanisms involved are not fully 
understood. Protein Kinase C (PKC) family members are a group of phospholipid-dependent 
serine/threonine kinases that regulate signaling pathways involved in cellular growth, 
proliferation, differentiation, and cell death. PKC signaling pathways have also been implicated 
in diseases such as DN. Specifically, PKCα has been shown to play a role in the development of 
albuminuria in mice with streptozotocin (STZ)-induced type 1 diabetes. The objective of this 
study was to determine whether PKC is a meprin substrate. To this end, activated forms of 
purified recombinant meprin A and B were incubated for 0-4 h with cytosolic-enriched proteins 
from either protein lysates extracted from Mardin-Darby canine kidney (MDCK) cells (which do 
not express meprins) or meprin αβ double knockout mouse kidneys (which lack endogenous 
meprins).   The levels of PKCα were determined by Western blot analysis using anti-PKCα 
specific antibodies. Incubation with meprin B significantly reduced the levels of PKCα present in 
the kidney and MDCK lysates. This decrease was not observed in proteins incubated with 
meprin A or control reactions lacking meprins, suggesting isoform-specific degradation of 
PKCα.  To confirm the degradation, human PKCα was expressed in yeast, purified by GST-
affinity chromatography, and incubated with the activated meprins.  To determine whether 
meprin cleavage of PKCα occurs in models of diabetes, immunohistological analysis was 
conducted using mouse kidney tissues from STZ-diabetes induced mice. These data suggest that 
meprin B may impact kidney function via proteolysis of PKCα. 
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1 CHAPTER 1 
Introduction 
Diabetes mellitus is a chronic disorder caused by an inherited and/or acquired deficiency 
in the production of insulin by the pancreas and/or by resistance to insulin’s effects (Evicmen & 
King, 2007). Diabetes and its complications affect many people worldwide, with a greater 
prevalence in developed countries. The number of people in North America who suffer from 
diabetes has increased substantially over the past two decades. Moreover, the increased blood 
glucose levels, or hyperglycemia, associated with diabetes causes damage to many body systems, 
including the eyes, nerves, and kidneys. Indeed, chronic hyperglycemia is believed to be the 
major cause of several diabetic complications, such as hypertension, diabetic nephropathy (DN), 
diabetic retinopathy (DR), and impaired wound healing. Previous studies in the United Kingdom 
have demonstrated that treatment that lowers blood glucose reduces the risks of diabetic 
retinopathy, nephropathy, and neuropathy (American Diabetes Association, 2002). 
Diabetic nephropathy (DN), which is kidney disease associated with long-standing 
diabetes, is the leading cause of end-stage renal disease (ERSD). It is the most common cause of 
progressive chronic kidney disease and ESRD in the Western world (Menne, 2013). Activation 
of Protein Kinase C (PKC) by hyperglycemia has been implicated in the induction of DN 
(Geraldes & King, 2010). Indeed, PKC isoform-selective inhibitors represent promising new 
therapeutics that have been shown to delay the onset or even stop the progression of diabetic 
vascular disease with very few side effects (Evicmen & King 2007). 
PKC, a founding member of the PKA/PKG/PKC (AGC) family of serine/threonine 
protein kinases, plays a key role in a variety of cellular functions by regulating many signal 
transduction pathways (Newton, 2003). PKC is activated by elevated levels of second 
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messengers, such as diacylglycerol (DAG) and calcium ions. The PKC family can be divided 
into three major sub-groups based on their mode of activation. These include the conventional 
PKCs (cPKC), which are regulated by both Ca2+ and DAG, the novel PKCs (nPKC), which are 
regulated by DAG but are insensitive to Ca2+, and the atypical PKCs (aPKC), which are 
insensitive to both DAG and Ca2+. Each group contains specific isoforms that are believed to 
have distinct cellular functions. This study focuses on the conventional PKC isoform, PKCα. 
PKCα can be activated by many stimuli, including mechanical strain, physical stress, such as 
hypoxia, and receptor activation (Nakashima, 2002). PKCα has been implicated in the 
pathogenesis of DN (Geraldes, 2010). The inappropriate activation of PKCα during DN is the 
impetus for this study. 
Meprins are metalloproteinases that are highly expressed at the brush border membrane 
(BBM) of kidney epithelial cells (Norman, 2003). Meprins are also expressed in podocytes, skin, 
and leukocytes (Ongeri, 2012). They are known to degrade extracellular matrix proteins (Dimas, 
2013) and have been implicated in the progression of kidney injury. In addition to their role at 
the membrane, meprins are able to redistribute from the BBM to the cytosol and basolateral 
membranes of kidney proximal tubular cells under conditions of ischemia reperfusion (Bylander, 
2008; Ongeri, 2011). Importantly, the redistribution of meprins to the cytosol appears to have 
functional consequences. 
Previous studies in our lab demonstrated that the catalytic subunit of another AGC family 
member, the alpha-isoform of the catalytic subunit of Protein Kinase A (PKA Cα), is cleaved by 
meprin metalloproteinases in an isoform-specific manner (Niyitegeka, in press, AJP-Renal). For 
instance, meprin B cleaves PKA Cα at both its N- and C-terminus while meprin A fails to cleave 
PKA Cα. The C-terminal cleavage site of meprin B, which reduces the catalytic activity of PKA 
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Cα nearly 20-fold, is conserved among several AGC family members, including PKCα (Figure 
1). 
Figure 1. Conservation of Meprin B Cleavage Site among AGC family Members.  (A) Schematic 
diagram showing the domain structure of the catalytic subunit of PKA (PKA Cα) and sites of 
Meprin B cleavage at the N- and C-termini (BI and BII, respectively). (B) Multiple sequence 
alignment of several AGC family members. Site BII in (A) (highlighted in red), is conserved in 
many PKC isoforms, including PKCα, the focus of this study (highlighted in blue).  
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2 CHAPTER 2 
Literature Review 
2.1 Diabetes 
Diabetes mellitus is a chronic disease caused by an inherited and/or acquired deficiency 
in the production of insulin by the pancreas (type 1 diabetes) or by resistance to insulin’s effects 
(type 2 and gestational diabetes) (Evcimen & King, 2007).  Diabetes, which is characterized by 
hyperglycemia due to insulin deficiency, affects nearly 170 million people worldwide and is 
expected to double by 2030 (Geraldes & King, 2010). More than 80 % of diabetes cases are 
found in developed countries. There are three types of diabetes: type 1, type 2, and gestational 
diabetes.  Type 1 diabetes is an autoimmune disease that results in the destruction of insulin-
producing pancreatic beta cells, leading to insulin deficiency. Type 2 diabetes, which affects 80-
90 % of all diabetes patients, is caused by insulin resistance. Finally, gestational diabetes is 
caused by insulin resistance that is first seen during pregnancy (Venkat-Narayan, 2006). 
Many complications stemming from diabetes have been observed. Such diabetes-
associated disorders are the result of interactions among a number of systemic metabolic 
abnormalities, including hyperglycemia, dyslipidemia, disruption of genetic/epigenetic 
modulators, and local tissue responses to toxic metabolites (Geraldes & King, 2010). For 
instance, DN is the major cause of end-stage renal disease (ESRD) in the developed world, 
accounting for 40 % to 50 % of all documented cases (Molitch, 2008). 
Chronic hyperglycemia is considered one of the major causes of diabetic complications. 
Macrovascular (involving large blood vessels) and microvascular (involving small blood vessels) 
complications are particularly prevalent in those patients with type 2 diabetes. Several organs, 
such as muscle, skin, brain, heart and kidneys, are affected by macrovascular and microvascular 
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complications attributed to diabetes (Cade, 2008).  These complications involve large vessel 
obstructions, such as coronary artery diseases, atherosclerosis, and peripheral vascular diseases, 
as well as microvascular pathologies, including retinopathy, neuropathy and nephropathy 
(Geraldes & King, 2010). 
2.2 Diabetic Nephropathy 
Diabetic nephropathy (DN) is a progressive and serious complication of diabetes caused 
by angiopathy that damages the kidneys, which can ultimately lead to renal failure. DN is 
characterized by a set of structural and functional hallmarks that occur in diabetic patients, 
including proteinuria, cellular hypertrophy and increased extracellular matrix protein production 
(Reeves & Andreoli, 2000). DN is the leading cause of ESRD, with a high mortality and 
morality rate in the United States, accounting for almost 40 % of all new dialysis patients 
(Reeves & Andreoli, 2000). Certain populations, such as American Indians, Hispanics and 
African Americans, are at greater risk of developing DN than Caucasians (Reeves & Andreoli, 
2000).  Interestingly, patients with type 2 diabetes have a higher occurrence rate of DN 
compared to those with type 1 diabetes. 
2.2.1 Complications due to diabetic nephropathy 
A set of structural and functional abnormalities in the kidneys of diabetic patients 
characterize DN.  DN is first characterized by microalbuminuria, which worsens to overt 
albuminuria followed finally by acute renal failure (ARF) (Cade, 2008). In diabetic kidney 
disease, cellular hypertrophy, thickening of the glomerular basement membrane (GBM) and 
tubular basement membrane (TBM) occur (Wada & Makino, 2013). During DN, production of 
ECM surpasses degradation, causing ECM proteins to build up in the glomerular and 
tubulointerstitial compartments and to manifest as glomerulosclerosis and tubulointerstitial 
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fibrosis in the affected kidney (Wada & Makino, 2013).  Recent evidence suggests that ECM 
accumulation is linked to elevated levels of transforming growth factor-β (TGF-β) in the diabetic 
kidney, which is caused by high glucose levels (Lee, 2013). 
The cellular and structural changes outlined above lead to a number of functional 
alterations in DN. Functional alterations include an early increase in the glomerular filtration rate 
with intraglomerular hypertension, subsequent proteinuria, systemic hypertension, and eventual 
loss of renal function (Reeves & Andreoli, 2000). One in four people with type 2 diabetes have 
microalbuminuria or a more advanced stage, which worsens at a rate of 2% a year (Cade, 2008).  
Although there has been extensive research on this complication of diabetes, its pathophysiology 
is not fully understood. 
2.2.2 Signaling pathways associated with diabetic nephropathy 
Diabetic nephropathy (DN) is characterized by a plethora of abnormalities, which lead to 
progressive albuminuria, podocyte loss, progressive glomerular sclerosis and tubulointerstitial 
fibrosis associated with the disease (Brosius, 2010). For instance, glucose-dependent pathways 
that are activated within the diabetic kidney include those that lead to increased oxidative stress, 
renal polyol formation and glycated end-products (Cooper, 2001). There are three major 
pathways associated with the development of DN: (i) the activation of polyol and PKC 
pathways; (ii) the formation of advanced glycation end-products; and (iii) intraglomerular 
hypertension induced by glomerular hyperfiltration (Wada & Makino, 2013). 
Haemodynamic factors are also known to have implications in the pathogenesis of DN. 
These include increased systemic and intraglomerular pressure and activation of various 
vasoactive hormone pathways, including the renin-angiotensin system and endothelin (Cooper, 
2001). Signaling enzymes, such as PKC and MAP kinase, as well as their downstream effectors, 
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such as TGF-beta, can become activated by haemodynamic pathways either independently or in 
the context of metabolic pathways. These pathways lead to increased renal albumin permeability 
and extracellular matrix accumulation, which results in increasing proteinuria, 
glomerulosclerosis and tubulointerstitial fibrosis (Cooper, 2001), all of which are characteristics 
of DN. Since there are multiple factors that contribute to the pathogenesis of DN, it is difficult to 
establish a hierarchy of signaling pathways involved in the disorder (Brosius, 2010). 
2.2.3 Intersection between the PKC signaling pathway and diabetic nephropathy 
There are a host of diabetic legions associated with DN. For instance, hyperglycemia, 
glycosylated proteins, intracellular polyols, vasoactive hormones, systemic and glomerular 
hypertension, proteinuria, growth factors, and cytokines have all been implicated in the 
pathogenesis of DN (Reeves & Andreoli, 2000). These mediators may lead to the inappropriate 
activation of PKC. Inappropriate activation of PKC and its isoforms alter insulin action on blood 
vessels, causing vascular abnormalities and pathologies. Hyperglycemia may be the most 
important factor in causing these vascular abnormalities and is considered to be the driving force 
of ESRD (Wada & Makino, 2013). 
High glucose levels, as well as its glucose metabolites, can affect vascular cell function 
directly via various signaling pathways (Evcimen & King, 2007). The DAG-PKC signaling 
pathway is a widely studied pathway indicating how diabetes may induce vascular 
complications. It is believed that hyperglycemia alters signaling pathways, causing cellular 
dysfunctions and damage (Geralds & King, 2010). Activation of the DAG-PKC pathway, which 
enhances polyol pathways, leads to increased oxidative stress, and causes overproduction of 
advanced glycation end products, has been proposed as a mechanism by which hyperglycemia 
induced diabetic vascular complications, such as DN, may arise (Noh & King, 2007) (Figure 2). 
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For instance, previous research demonstrated that PKCα-deficient mice were protected against 
albuminuria, suggesting that PKCα activation is linked to DN (Menne, 2006). Although it is 
known that PKC activation is correlated to vascular complications in diabetic patients, the 
mechanisms are not fully understood. 
Figure 2. Schematic representation of various biological targets of PKC activation leading to 
diabetic nephropathy (adapted from Geralds, 2010). 
2.3 Protein Kinases 
Protein kinases comprise a sophisticated family of enzymes that regulate the function of 
nearly all cellular functions. Eukaryotic protein kinases modify other proteins by catalyzing the 
transfer of a phosphate group to Ser, Thr or Tyr residues located within their protein substrate. 
The human genome contains 518 protein kinase genes, constituting approximately 2% of all 
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human genes (Manning, 2002). Up to 30 % of all human proteins are believed to be modified by 
protein kinases (Manning, 2002). As a consequence, protein kinases have rapidly become major 
therapeutic targets. 
One of the most well studied kinase family members, PKC, mediates a variety of 
physiological responses within a cell. PKC family members are phospholipid-dependent 
serine/threonine kinases that play key roles in signaling pathways involved in regulating cellular 
growth, proliferation, differentiation and cell death (Freeley, Kelleher & Long, 2011). PKC 
function, like most protein kinases, is influenced by phosphorylation, which has a central role in 
its structure and function. In particular, three conserved phosphorylation sites located in the 
activation loop, the turn motif, and the hydrophobic-motif are important in controlling the 
catalytic activity, stability and intracellular localization of the enzymes (Freeley, Kelleher & 
Long, 2011). 
PKC family members, like all other eukaryotic protein kinases, are characterized by an 
N-terminal lobe consisting almost entirely of -sheets and a C-terminal lobe composed primarily 
of -helices (Figure 3) (Taylor & Kornev, 2011). The kinase active site, which is involved in 
both ATP and substrate binding, lies at the cleft formed between the N- and C-terminal lobes. 
The N-terminal regulatory domain has two main functions. First, it contains a pseudosubstrate 
sequence that binds to the substrate-binding cavity and blocks catalytic activity. Binding of the 
pseudosubstrate region is modulated by several regulatory elements located in the N-terminal 
lobe, including the C1 domain (involved in DAG binding), the C2 domain (involved in Ca2+ 
binding), and, in the case of atypical PKC (aPKC) family members, the PB1 domain (involved in 
protein-protein interactions and phosphatidylserine binding) (Yang, 2012; Freely, 2011). These 
regulatory domains are also useful in distinguishing between different PKC subfamilies. 
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Currently, nine PKC isoforms have been cloned and characterized. The nine PKC isoforms are 
classified into three subgroups based on the presence or absence of functional C1 and C2 
domains (Figure 3). For example, the conventional PKCs (cPKCs), which are comprised of 
PKCα, β1, β2 and  contain both a functional C1 domain and a functional C2 domain. 
Meanwhile, the novel PKCs (nPKCs), which consist of PKC δ, ε, η and θ, contain a functional 
C1 domain but lack a functional C2 domain, thereby rendering them insensitive to Ca2+. Finally, 
the aPKCs, which are comprised of PKC ζ and , contain neither a functional C1 domain nor a 
functional C2 domain. Instead, aPKC family members contain a PB1 domain. These N-terminal 
regulatory elements are largely involved in regulating the subcellular distribution of PKC family 
members. For instance, interactions between the C1 domain and the lipid second messenger, 
DAG, promote the redistribution of cPKC and nPKC family members from the cytoplasm to the 
plasma membrane. In addition, conformational changes induced by the regulatory elements 
releases the pseudosubstrate, allowing subsequent binding and phosphorylation of the substrate 
(Freely, 2011). 
The C-terminal lobe is also critical to PKC function. For instance, the C-terminal lobe 
contains the C3 and C4 domains, which provide critical contacts with ATP and the substrate, 
respectively, in the active site binding cleft (Nakashima, 2002).  Moreover, phosphorylation sites 
located on the C-terminal activation loop, the turn motif, and hydrophobic-motif are important to 
PKC function. Many of these phosphorylation sites are conserved in other AGC family 
members, including the canonical ABC kinases (PKA, PKB/Akt, PKC). Importantly, a non-
conserved hinge domain found in PKC family members, known as the V3 region, is present 
between the N- and C-terminal lobes.  When PKC is active, this V3 “hinge” domain may be 
susceptible to proteolytic enzymes. 
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This study focuses on PKCα. PKCα is a serine/threonine kinase and a member of the 
conventional (classical) PKCs (cPKCs), which have four conserved (C1 to C4) regions. This 
PKC isotype is activated in response to many different kinds of stimuli and translocates from the 
cytosol to distinct subcellular compartments (e.g., nucleus, sites of focal adhesion, caveolae, etc.) 
where it acts to phosphorylate its downstream effectors. Therefore, PKCα has been implicated in 
a variety of cellular functions, including proliferation, apoptosis, differentiation, motility, and 
inflammation. However, the responses induced by activation or overexpression of PKCα vary 
depending on the cell type as well as cellular conditions. For example, in MCF-7 human breast 
cancer cells and the human glioma U87 cell line, PKCα has been implicated in cell growth 
(Nakashima, 2002). In contrast, it may play a role in cell cycle arrest and differentiation in other 
types of cells, such as melanoma and lens epithelial cells (Nakashima, 2002). Therefore, 
alterations of cell responses induced by PKCα are not an intrinsic property of this isoform. 
Rather, the responses are modulated by dynamic interactions with cell-type specific factors: 
substrates, modulators and anchoring proteins. 
2.4 Meprins 
Meprins are multidomain zinc metalloproteinases of the astacin family that are highly 
expressed at the brush border membranes (BBM) of proximal kidneys tubules and small 
intestines (Norman, 2003).  Meprins are also expressed in leukcocytes (Sun, 2009) and certain 
cancer cells (Norman, 2003).  Meprins have been implicated in inflammation as well as cancer 
growth and metastasis. They are the only members of the astacin family that can be both secreted 
and membrane bound (Sterchi, 2008). In humans, two meprin genes exist, meprin α and β, that 
are located on chromosome 6 and 18, respectively. Meprin α and β are evolutionarily related, 
with their gene products exhibiting 42 % identity at the amino acid level and sharing the same 
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domain structure (Norman, 2003). The gene products of meprin α and β associate to form either 
homo- or hetero-oligomers with a multi-domain structure that forms covalent and non-covalent 
dimers and/or tetramers. For instance, Meprin A consists of a homodimer of meprin  subunits 
or heterooligomer of α-and β subunits while meprin B is a meprin  homo-oligomer. 
Importantly, while meprin B and the heteromeric isoform meprin A (α/β) remains membrane-
associated due to an integral membrane domain, meprin A (α/α) is secreted (Bond, 2005). 
2.4.1 Meprin substrates 
Meprins are capable of hydrolyzing many substrates in vitro, including extracellular 
matrix (ECM) proteins (e.g., collagen type IV, laminin, fibronectin and nidogen), cytokines (e.g., 
interleukin-1b), hormones (e.g., insulin), and small peptides (e.g., gastrin 17, cerulein, and sCCK 
8 of the gastrointestinal tract) (Hahn, 2003; Oneda, 2008).  In addition, these proteases also have 
the ability to cleave cytoskeletal proteins, such as actin and villin, and bioactive peptides, such as 
TFG-α and angiotensin (Huguenin, 2008; Ongeri, 2011). Although there are common substrates 
between meprin A and meprin B, the actual sites of cleavage are isoform specific. For example, 
meprin B preferentially cleaves acidic amino acids in the P1 sites while meprin A prefers small 
(e.g. serine, alanine) or hydrophobic (e.g. phenylalanine) residues in the P1 sites (Bertenshaw, 
2001). Therefore, it has been suggested that meprins are involved in the modulation of the 
activity of important extracellular proteins and signaling peptides (Hahn, 2003). Recently, we 
demonstrated that the catalytic subunit of protein kinase A (PKA) is cleaved by the 
metalloproteinase Meprin B at its C-terminus, causing an ~20-fold decrease in kinase activity 
(Niyitegeka, in press, AJP-Renal). The site that is cleaved by Meprin B is highly conserved 
among various protein kinases, including several PKC family members. We believe that PKC 
may also be cleaved at the conserved site by meprin B. In addition, we and others have 
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demonstrated that meprin-mediated cleavage of PKA, alters its kinase activity, suggesting 
potential functional consequences. 
2.4.2 Meprins and diabetic nephropathy 
Merpin proteinases have the potential to be detrimental at the site of tissue damage, such 
as in acute renal injury. Linkage analysis has implicated meprin β as a candidate gene for DN in 
the Pima Indian population, in which 92% of ESRD was attributed to DN (Norman, 2003).  
Moreover, the meprin β locus on chromosome 18 has been linked to a greater risk of DN in 
patients with type 2 diabetes (Mathew, 2005).  
 The two meprin isoforms are deleterious in renal tissue, which indicates a contribution to 
renal injury. This proteolytic activity of meprins in renal injury indicates multiple functions in 
health and disease; however, the specific mechanisms underlying these functions are not well 
understood. The role of metalloproteinases in basement membrane remodeling in particular has 
recently received a lot of attention due to their ability to influence the progression of renal 
dysfunction (Oneda, 2008). 
In transfected cells, intracellular proteolytic removal of the membrane anchor results in 
the secretion of the meprin α subunit. In human meprin, its subunit is converted into a secretable 
form, unlike mouse and rat meprin (Hahn, 2003).  Previous research demonstrated that human 
meprin is phosphorylated following treatment with phorbol 12-myristate-13-acetate (PMA), a 
PKC-activating phorbol ester. Interestingly, the site of phosphorylation, Ser687, lies within a 
PKC consensus sequence located in the cytosolic domain of the protein (Hahn, 2003). 
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3 CHAPTER 3 
Methodology 
3.1 Reagents 
Monoclonal mouse anti-PKCα and anti-PKCβe antibodies were purchased from BD 
Biosciences (Franklin lakes, NJ). Dulbecco’s modified Eagle media (DMEM) was purchased 
from Gibco (Grand Island, NY). Beta-mercaptoethanol, glycerol, Tris base, sodium chloride, 2-
[4-(2-hydroxyethyl)piperazin-1yl]ethanesulfonic acid (HEPES) and ethylenediaminetetraacetic 
acid (EDTA) were purchased from Amresco, Inc. Yeast nitrogen base without ammonium sulfate 
and without amino acids, galactose, ethanol, glacial acetic acid, sodium orthovanadate, ethyl 
alcohol (200 proof) and Tween 20 were purchased from Fisher Chemical (Pittsburgh, PA). SC-
URA power mix was purchased from MP Biomedicals (Solon, OH). 
Tetramethylethylenediamine (TEMED), sodium citrate, and sodium dodecyl sulfate were 
purchased from Sigma-Aldrich (St Louis, MO).   The following chemicals were purchased from 
Bio-Rad (Hercules, CA): blocking grade milk, silver stain plus kit, 40% acrylamide solution, 
EZRun pre-stained protein ladder, anti-rabbit IgG . 
3.2 Meprin Incubations to Determine PKC Cleavage/Degradation 
 To determine whether PKC is cleaved/degraded by meprins, cytosolic-enriched cell 
lysates from meprin αβ double knockout mouse kidney tissue and cell lysates from Mardin-
Darby canine kidney cells (MDCK) cells were incubated with either active, recombinant human 
Meprin A (α-α) or recombinant rat Meprin B (β-β) for 0-4 hours. 20 L aliquots were removed 
from the reaction at 0, 0.5, 1, 2, 3, and 4h.  The reaction was quenched by adding 4 L of 6x 
SDS-loading buffer. Each sample was then loaded into a 15-well 1.5mm 10 % SDS-
polyacrylamide gels, using 20 µl for each lane. Western blot analysis was conducted to quantify 
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the levels of PKCα present, as described below. In addition to cell lysates, recombinant human 
PKCα, purified from yeast by GST-affinity chromatography, was incubated with Meprin B for 4 
h and analyzed by western blot. 
3.3 Western Blot Analysis 
Western blot analysis was used to assess cleavage and to quantify the levels of PKCα in 
lysates from Mardin-Darby canine kidney cells (MDCK) and cytosolic-enriched αβ double 
knockout mouse kidney proteins incubated with meprins. Following incubations, proteins were 
separated by electrophoresis on a 10 % acrylamide gel and transferred to a nitrocellulose 
membrane. Non-specific binding sites were blocked by incubation for 1 h at room temperature in 
5-8% fat-free milk in Tris-buffered saline with 0.05% Tween-20 (TBS-T). To determine the 
levels of PKCα and PKC expressed in MDCK and kidney proteins, membranes were incubated 
with mouse monoclonal anti-PKCα and anti-PKCβ antibodies (BD biosciences), respectively, 
diluted 1:1000 in TBS-T, in TBS with 1 % bovine serum at RT for 1h or at 4o C overnight. Anti-
mouse IgG-HRP conjugate (Thermos Scientific), diluted 1:10,000 in TBS-T, was used as 
secondary antibodies.  Bands were detected by chemiluminescence after adding ECL substrate to 
the membranes and developed on X-ray film. 
3.4  Cell Culture and Protein Extraction for HEK 293 cells 
Cell culture was used to grow non-transfected, meprin α-transfectedand, meprin β-
transfected human embryonic kidney cells (HEK 293). Dubelcco’s modified Eagle media 
(DMEM) with 4.5g/L glucose supplemented with 10 % Fetal Bovine Serum (FBS) was warmed 
in a water bath for 30 minutes at 37 °C. After media was warmed, 10 ml of DMEM media was 
added to each 10 cm2 cell culture dish. Cells were incubated in a CO2 incubator set at 37° C, 5% 
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CO2 and 85% humidity until they reached 70-90 % confluence. The media was then changed to 
DMEM media supplemented with 2.5 % FBS and the cells cultured overnight. 
3.5 Protein Extraction 
Total proteins were extracted from HEK 293 and MDCK cells. The 100 cm2 cell culture 
dishes containing the cells were rinsed with ice-cold sterile phosphate buffered saline (PBS) 
three times. 500 l of radioimmunoprecipitation assay (RIPA) buffer (1M Hepes,1M NaCl,10% 
Triton-X-100, 10% SDS,100 mM  Na3OV4, 0.5M EDTA and 100X protease inhibitor cocktail) 
was added to each dish to extract total protein and incubated on ice for 30 minutes. Cells were 
harvested using a cell scraper and transferred to 1.5 ml centrifuge tubes. Cells were centrifuged 
for 30 minutes at 21,000 x g at 4 °C. Finally, supernatants, containing the cell lysate were 
transferred to new centrifuge tubes for western blot analysis.  
3.6 Purification of Recombinant PKC Proteins 
Human PKCα containing an N-terminal GST affinity tag was purified from yeast using 
GST-affinity chromotography. Accordingly, a single colony of yeast transformed with a yeast 
expression vector encoding GST-PKCα was used to innoculate 5 mL of SC-URA(-) culture 
media supplemented with 20 % (w/v) glucose and grown overnight (approximately 16 hours 
until saturation).  The following evening, 100 μl of the overnight culture was used to inoculate 
50 mL of SCR-URA(-) supplemented with 20 % (w/v) raffinose for approximately 16 hours at 
30 °C in an incubator shaker (200 rpm). Once the culture reached an optical density between 0.6 
and 1.0 OD600, PKC expression was induced for six hours by the addition of 40 % (w/v) 
galactose to a final concentration of 2 % (w/v). Time points were taken every 2 hours and used to 
assess induction. Following induction, cells were pelleted for 3 minutes at 850 x g in 50 ml 
conical tube, washed with dH2O and stored at -80 º C until purification. To purify GST-PKC, 
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cells were lysed by mechanical lysis and purified by GST-affinity chromatography, as described 
(Newman, 2013). Following purification, the purity of GST-PKCα was assessed by silver 
staining. 
3.7 SDS-PAGE and Silver Staining 
Purified GST-PKCα was incubated in the presence or absence of recombinant purified 
Meprin B for 4 h. Aliquots (20 L each) were removed at the indicated time points and the 
reaction was quenched by the addition of 4 L of 6x SDS-loading buffer. Samples were then 
loaded onto a 10 % SDS-PAGE gel and resolved at 200 volts for ~45 minutes. To assess the 
extent of cleavage, the bands were visualized by silver stain analysis according to the 
manufacturer’s protocol. Briefly, the acrylamide gel was placed in fixative enhancer solution for 
20 minutes before being rinsed in deionized distilled water for 2 x 10 minutes. Samples were 
stained with development accelerator solution until desired staining intensity was reached. To 
stop staining, the gel was placed in 5 % acetic acid stop solution for ~15 minutes. 
3.8 Glucose Treatment of Human Embryonic Kidney (HEK) 293 cells 
We used HEK293 cells transfected with cDNA for meprin α and meprin β to determine 
the impact of meprins on PLC expression following exposure to high glucose. Non-transfected 
cells were used as controls.  Three glucose concentrations were used for each genotype of cells; 
no glucose (0 mM), low glucose (5 mM), and high glucose (25 mM).  The cells were first 
cultured in DMEM supplemented with 10% FBS and antibiotic/antimycotics in a CO2 incubator 
at 37 oC and 5 % CO2 to 50 % confluence.  The culture media was then changed to a reduced 
serum media (2.5 % FBS).  Glucose dissolved in PBS was then added to a final concentration of 
5 mM or 25 mM.  An equivalent volume of PBS was added to the 0 mM, no glucose control.  
The cells were cultured for an additional 48 hours. Protein lysates were extracted as described in 
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section 3.4 above.  Proteins were separated by gel electrophoresis and analyzed using Western 
blot analysis with anti-PKCα specific antibodies.  The protein levels were quantified by optic 
densitometry using Bio-Rad’s GS800 scanner.  The intensities for tubulin were used as a loading 
control. 
3.9 Immunofluorescence Analysis of Kidney Tissue for PKC and Meprins 
We used immunofluorescence (IF) to analyze paraffin-embedded kidney tissues from 
wild-type mice with STZ-induced type 1 diabetes. For the deparaffinization step slides, each 
slide was placed in xylene for 5 minutes three times. Next, slides were placed in 100% ethanol 
for 10 minutes two times. Slides were placed in 95 % ethanol for ten minutes two times. Slides 
were placed in deionized distilled water for 5 minutes 2 times. Antigen unmasking step slides 
were brought to a boil in 10 mM sodium citrate, pH 6.0, for 10 minutes. Slides were cooled for 
30 minutes and rinsed in 10x PBS. Immunostaining slides were blocked in blocking buffer (1X 
PBS , normal goat serum, and Triton X-100) for 60 minutes in a humidity chamber. Next, slides 
were incubated with primary mouse monoclonal anti-PKCα antibodies (diluted1:100), rabbit 
polyclonal anti-meprin B (HMC77) (diluted 1:400) or rabbit polyclonal anti meprin A antibodies 
(HMC14) diluted 1:200) overnight. Slides were rinsed 3 times in 1x PBS for 5 minutes each. 
Slides were incubated with fluorophore-conjugated secondary antibodies rabbit Alexfluor488 
(1:1000 dilution) and/ or mouse Alexafluor555 (1:1000 dilution) with DAPI for 1 hour at room 
temperature in the dark. Slides were rinsed three times in 1x PBS for 5 minutes each. Prolong® 
Gold Anti-Fade Reagent was added to slides before coverslips were mounted and left to dry 




4.1 Meprin B Degrades PKCα Present in Kidney Proteins and Kidney Cell Lysates. 
To determine whether meprins cleave PKCα present in cells derived from native tissue, 
kidney tissue lysates from αβ-knockout (KO) mice were incubated with activated forms of 
purified meprin A and meprin B, and PKCα levels were assessed by Western blot analysis 
(Figure 3). While no change in PKCα levels was observed after a 4 h incubation with meprin A, 
a marked reduction in PKCα levels was observed after only 0.5 h incubation with meprin B, with 
PKCα levels decreasing below the detection limit of the assay after 2 h.  These results suggest 
that PKCα is degraded by the meprin B isoform in a time-dependent manner. 
Figure 3. Meprin degradation of PKCα present in kidney proteins from meprin αβ double 
knockout mice. 
The same outcome was observed when MDCK cell lysates (which do not normally 
express meprins) were incubated with meprin A and meprin B and PKCα levels were analyzed at 
various times over the course of the reactions (Figure 4). While PKCα levels did not change 
following incubation with Meprin A, PKCα levels decreased dramatically after 0.5 h of 
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incubation with Meprin B. The levels of PKC continued to decrease in a time-dependent 
manner at the 1 h and 2 h time points until no PKC could be observed after 3 h. Together, these 
data suggest that PKCα is preferentially cleaved by meprin B in a time dependent manner. 
Figure 4. PKCα levels in MDCK cell lysates incubated with active meprin A and meprin B. 
In order to confirm that PKCα is degraded by meprin B, recombinant PKCα was purified 
by GST-affinity chromatography, incubated with active meprin B for 3 h, and the products 
analyzed by Western blot (Figure 5).  In the absence of meprin B, recombinant PKCα migrated 
as a doublet, presumably corresponding to the phosphorylated (active) and unphosphorylated 
forms of the protein. Interestingly, only the upper band decreased following incubation with 
meprin B, raising the possibility that meprin B preferentially cleaves the phosphorylated form of 
recombinant PKCα. Further studies are currently underway to test this hypothesis. 
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Figure 5. Immunoblot of PKCα following incubation of purified recombinant PKCα with 
activated purified meprin B.  In order to confirm that degradation of PKCα is meprin B-specific, 
recombinant PKCα was purified by GST-affinity chromatography, incubated with active meprin 
B for 3 h, and the products analyzed by western blot (unphosphorylated and a putatively 
phosphorylated species are indicated).  
4.2 Impact of Glucose Treatment on PKCα Expression in HEK 293 Cells 
To determine the impact of meprin expression on PKCα in cells exposed to a high 
glucose environment, either untransfected, meprin α-transfected or meprin β-transfected 
HEK293 cells were treated with 0 mM (no glucose control), 5 mM (low glucose) or 25 mM 
(high glucose) (Figure 6). Western blot analysis was used to assess the levels of PKC. 
Untransfected cells appeared to have lower relative PKCα baseline levels than meprin α and 
meprin β transfected cells. 
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Figure 6. Effect of glucose treatment on PKCα levels in HEK 293 cells. To determine the impact 
of meprin-mediated cleavage of PKCα in cells exposed to a high glucose environment, either 
untransfected, meprin α-transfected or meprin β-transfected HEK293 cells were treated with 0 
mM (no glucose control), 5 mM (low glucose) or 25 mM (high glucose). Western blot analysis 
was used to assess the levels of PKCα.  The graph above shows the optical density of anti-
tubulin and anti-PKCα blots. Untransfected cells appeared to have lower band intensity than 
meprin α- and meprin β-transfected cells. 
4.3 Impact of Diabetes on PKCα Levels In Vivo 
Recent studies suggest that meprins are not only activated at the plasma membrane in 
models of diabetes and diabetic nephropathy, but that they are also redistributed to the cytosol 
where they act on cytosolic proteins (Bylander, 2008; Ongeri, 2011). Therefore, it is possible that 
meprins can act on PKC in vivo under conditions of chronic or acute kidney damage. To 
examine this question further, immunofluorescence was employed to determine the distribution 
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of meprins and PKC in kidney tissues derived from non-diabetic and diabetic mice. In the non-
diabetic control and diabetic kidney tissues, meprin A is only seen in the brush border membrane 
of proximal kidney tubules (Figure 7). In comparison to the non-diabetic control, the diabetic 
mouse kidney tissues showed meprin A in the glomerulus (Figure 8). 
Figure 7. Immunofluorescence images of control (top) and STZ-treated (bottom) kidney tissue 
for PKCα and meprin A in kidney tubules (green: meprin A; red: PKCα; blue: DAPI-stained 
nuclei). 
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Figure 8. Immunofluorescence analysis of control (top) and STZ-treated (bottom) kidney tissue 













11 CHAPTER 5 
Discussion and Future Research 
Diabetic nephropathy is the leading cause of ESRD with high mortality and morbidity 
rates (Reeves & Andreoli, 2000). In the U.S., DN accounts for about 40 % of new cases of 
ESRD (Molitch, 2008). Complications of DN include a set of structural and functional 
abnormalities within the kidney, such as cellular hypertrophy, an increase in the thickness of the 
glomerular basement membrane (GBM) and the tubular basement membrane (TBM), 
tubulointerstitial fibrosis, and mesangial cell expansion with extracellular matrix, also known as 
glomerulosclerosis (Wada & Makino, 2013). Meprins, which are metalloproteinases that are 
abundantly expressed at the BBM of kidney tubules, are known to degrade ECM proteins. 
Meprins are also expressed in podocytes, skin, and leukocytes. Inappropriate activation of 
protein kinase C (PKC) is known to have implications in DN progression. To examine the role of 
meprins in regulating intracellular PKCα activity, MDCK lysates and αβ-knockout kidney 
proteins were used to determine whether meprins cleave/degrade PKCα. Results from this study 
suggest that PKCα is cleaved by meprin B, but not meprin A. Our data indicate that PKCα 
degradation is specific to meprin B and occurs in a time dependent manner in both MDCK cell 
lysates and knockout kidney proteins. To further investigate whether cleavage of PKCα is 
meprin B-specific, recombinant PKCα was purified and incubated with activated meprin B. The 
phosphorylated form of PKCα seemed to be preferably cleaved by meprin B. Since PKCα is 
known to play a role in the pathogenesis of DN, knowing that it is a target for meprin B may 
provide a better understanding of the PKC pathway involvement in DN, and mechanisms by 
which meprins modulate kidney injury in DN. To access the impact of high glucose on PKCα 
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expression in the presence of meprins, HEK 293 cells were treated with no, low and high 
glucose. There was not a major difference in PKCα expression between meprin α- and β-
transfected cells. In comparison to non-transfected HEK 293 cells, the meprin-transfected cells 
appeared to have higher PKCα expression. This may indicate PKCα expression is being 
regulated by meprins under the influence of glucose. Additional experiments are needed to verify 
this claim. Finally the impact of diabetes on PKCα in the presence meprins was assessed using 
immunofluorescence analysis. The data show that PKCα is expressed in both tubular cells and 
cells in the glomeruli.  While meprin expression is predominantly in the BBM of proximal 
tubules, we observed glomeruli expression of meprin A in diabetic mice.  Meprin B may be an 
important factor in the PKC pathway, which may have important implications because meprins 
are known to have detrimental effects on kidney tissues (Bond, 2005).  The regulation of PKC in 
DN is not fully understood so overall results may indicate that PKCα is modulated by meprin B.  
Future studies need to be done to validate these claims. 
Though we have determined that PKCα is a substrate of meprin B, it is still not clear 
where on PKCα meprin B is cleaving. Therefore, mass spectrometry analysis will be performed 
to further evaluate the specific site(s) of meprin B cleavage in PKCα. Likewise, it will be 
important to understand the impact of meprin B cleavage on PKC activity and/or substrate 
selection. For the former, the activity of PKCα before and after meprin B-mediated cleavage will 
be determined using a model PKC substrate (e.g., the peptide substrate, PKCtide) while 
functional protein microarrays composed of ~19,000 unique human proteins can be used to 
assess the latter. Finally, though we have demonstrated that cleavage of PKC is meprin isoform 
specific with respect to the meprin isoforms, meprin A and B, in the future it will be interesting 
to determine whether meprin degradation is isoform specific with respect to other PKC family 
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members (e.g., PKC β1 and β2). Based on previous studies with the catalytic subunit of PKA, it 
is hypothesized that meprin B will affect PKC function by reducing or abolishing its activity.  
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